Canadian Journal of Cardiology

Amyloidosis Tissue Confirmation for Tafamidis Eligibility Using Transverse Carpal Ligament and Tenosynovium Biopsy


      In most Canadian provinces, eligibility criteria for public reimbursement coverage for tafamidis for treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM) include tissue biopsy confirmation of amyloidosis. Carpal tunnel syndrome requiring surgical release is common in ATTR-CM. We report our experience performing simultaneous transverse carpal ligament and tenosynovium biopsy during CTR, with all patients positive for amyloidosis, facilitating initiation of tafamidis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fine N.M.
        • Davis M.K.
        • Anderson K.
        • et al.
        Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
        Can J Cardiol. Mar 2020; 36: 322-334
        • Maurer M.S.
        • Schwartz J.H.
        • Gundapaneni B.
        • et al.
        Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
        N Engl J Med. Sep 2018; 379: 1007-1016
      1. Technology CAfDaH. Canadian Drug Expert Reimbursement Recommendations - Tafamidis Meglumine. Common Drug Review. Ottawa, Ontario, Canada 2020. p. 1-8.

        • Cooper L.T.
        • Baughman K.L.
        • Feldman A.M.
        • et al.
        The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
        Circulation. Nov 06 2007; 116: 2216-2233
        • Fine N.M.
        • Arruda-Olson A.M.
        • Dispenzieri A.
        • et al.
        Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.
        Am J Cardiol. May 15 2014; 113: 1723-1727